Ubs Group Ag Palisade Bio, Inc. Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$0.11 - $0.52 $8,704 - $41,149	79,133 Added 368.04%	100,634 $10,000
Q2 2022 Aug 10, 2022	BUY	$0.41 - $1.04 $5,490 - $13,927	13,392 Added 165.15%	21,501 $9,000
Q1 2022 May 16, 2022	BUY	$0.81 - $1.51 $3,462 - $6,455	4,275 Added 111.5%	8,109 $9,000
Q4 2021 Feb 14, 2022	BUY	$1.3 - $2.96 $2,041 - $4,647	1,570 Added 69.35%	3,834 $5,000
Q3 2021 Nov 15, 2021	SELL	$2.35 - $3.93 $46,703 - $78,104	-19,874 Reduced 89.77%	2,264 $6,000

Q2 2021 Aug 13, 2021	BUY	$3.49 - $11.34 $77,261 - $251,044	22,138 New	22,138 $90,000

Ticker PALI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,240,200
Market Cap $310M
Description
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzym...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.